Drug Patent Watch

JANUARY 9, 2025

The pharmaceutical landscape is evolving rapidly, with small and medium-sized biotech companies increasingly taking center stage in innovation. In 2017, small and medium-sized biotech companies accounted for 51% of FDA market approvals, while large pharma companies were the originators in only 28% of approvals[4].

Compliance

Pharma Manufacturing

JULY 9, 2025

The tariffs on pharmaceuticals would have a grace period of up to a year and a half to give drugmakers the opportunity to move their manufacturing operations to the U.S.

Pharma Companies

Drug Target Review

MAY 26, 2025

Even the largest of Pharma companies use CROs – the reason being that the in-depth scientific resources needed to support these technologies are just not cost-effective enough to have internally,” he explains. Almost without exception, CROs are involved in the development of novel therapies.

Drug Development

The Pharma Data

JUNE 6, 2025

As pharma companies grapple with mounting pressure from regulators, payers, and evolving market dynamics, the CSO model offers a compelling alternative to traditional, fully in-house sales forces.

Pharmaceutical Companies

Drug Patent Watch

APRIL 23, 2025

But what does this mean for pharma companies, investors, and patients? According to a recent analysis, the loss of exclusivity for top-selling medications will result in a staggering $1.4 trillion in lost revenue by 2025.

Marketing

BioPharma Drive: Drug Pricing

OCTOBER 1, 2024

Medical meetings often feature important clinical trial results, making them barometers of biotech and pharma companies' research progress. Here’s a list of conferences to watch in 2025.

Pharma Companies

BioPharma Drive: Drug Pricing

NOVEMBER 28, 2023

tax law changes enacted six years ago slashed large pharma companies' rates and saved them billions. Now, a push for an international floor could disrupt their R&D accounting.

International

BioPharma Drive: Drug Pricing

JANUARY 6, 2025

Esperion CEO Sheldon Koenig reflects on personal challenges and advancing innovative heart therapies.

Pharma Companies

BioPharma Drive: Drug Pricing

OCTOBER 9, 2024

Many pharma companies are now using de-identified lab data to identify potential patients and their physicians in time to impact the patient’s treatment plan. In this Q&A, learn how lab data can be used to increase patient access.

Treatment

Drug Patent Watch

MAY 13, 2025

"Unlocking the Secrets to Smarter Partnerships: How One Tool is Revolutionizing the Way Pharma Companies Approach Out-Licensing and Partnering Decisions As the pharmaceutical industry continues to evolve, companies are under increasing pressure to maximize their portfolios and minimize risk.

Licensing

BioPharma Drive: Drug Pricing

JULY 24, 2023

The Swiss pharma company is the latest large drugmaker to invest big in an experimental heart treatment, after years of prioritizing medicines for cancer and immune diseases.

Pharma Companies

DrugBaron

FEBRUARY 16, 2024

So what does the game look like to a late-stage investor or a pharma company head of R&D thinking about portfolio prioritisation? By contrast, if you behave like an early-stage investor with a good quality pharma company pipeline, you will likely kill value by under-investing or stopping projects that have real value.

Drug Development

BioPharma Drive: Drug Pricing

DECEMBER 12, 2023

The deal signals the pharma company’s continuing interest in vaccine development and hands it a combination shot aimed at two respiratory viruses.

Vaccine

BioPharma Drive: Drug Pricing

SEPTEMBER 3, 2024

Pharma companies can thrive in 2024 by leveraging digital intelligence to anticipate trends, analyze sentiment, and engage audiences. Discover how data-driven insights drive success.

Pharma Companies

BioPharma Drive: Drug Pricing

JULY 29, 2024

The pharma company will pay up to $1.3 billion to acquire San Diego-based Nerio and its research into novel immune checkpoint inhibitors.

Pharma Companies

BioPharma Drive: Drug Pricing

SEPTEMBER 25, 2023

Novartis has made a large investment in targeted radiotherapies, sparking competition from fellow pharma companies and young biotechs.

Pharma Companies

Drug Patent Watch

SEPTEMBER 17, 2023

This chart shows the drug companies with the most supplementary protection certificates (SPCs). SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating for the… The post Which pharma companies have the most supplementary protection certificates?

Pharma Companies

BioPharma Drive: Drug Pricing

JULY 10, 2023

The pharma company will pay $30 million upfront to gain rights to an experimental therapy meant to enhance the anti-tumor effect of radiation.

Licensing

BioPharma Drive: Drug Pricing

APRIL 14, 2025

Pharma companies are increasingly turning to real-world data to answer their commercial business questions, but not all realize that unstructured EMR

Pharma Companies

Drug Channels

OCTOBER 14, 2022

Today’s guest post comes from Steve Callahan, Senior Manager of Market Research at MMIT. Steve walks us through the expected Humira biosimilars launches and discusses potential responses from payers. To learn more, check out MMIT’s Strategic Launch Report & Evaluate Forecast solution. Read on for Steve’s insights.

Biosimilars

Drug Patent Watch

SEPTEMBER 18, 2022

This chart shows the drug companies with the most supplementary protection certificates (SPCs). The post Which pharma companies have the most supplementary protection certificates? SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating for the….

Pharma Companies

Drug Patent Watch

SEPTEMBER 17, 2021

This chart shows the drug companies with the most supplementary protection certificates (SPCs). The post Which pharma companies have the most supplementary protection certificates? SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating for the….

Pharma Companies

Drug Patent Watch

SEPTEMBER 16, 2020

This chart shows the drug companies with the most supplementary protection certificates (SPCs). The post Which pharma companies have the most supplementary protection certificates? SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating for the….

Pharma Companies

BioPharma Drive: Drug Pricing

JULY 18, 2023

The pharma company, which will soon split off its generic drug unit, plans to repurchase up to $15 billion of its shares through the end of 2025.

Pharma Companies

Vial

FEBRUARY 15, 2024

Pharmaceutical companies often face challenges in conducting clinical trials due to the need for substantial knowledge, time, and resources. To address these challenges, many companies outsource their clinical trials to contract research organizations (CROs) with established protocols, global reach, and therapeutic area expertise1.

Pharma Companies

Drug Patent Watch

FEBRUARY 2, 2021

In their coverage of Mark Cuban’s new pharma company, they cited our published interview where Mark Cuban Sounds off on Drug Prices.…. DrugPatentWatch was featured in a recent article by Inc. The post DrugPatentWatch featured in Inc Magazine appeared first on DrugPatentWatch - Make Better Decisions.

Pharma Companies

Drug Patent Watch

JULY 25, 2023

In a recent article published by IAM Magazine, titled “Why Pharma Companies Should File Patents Later In The R&D Process,” Alexander R. Trimble, PhD, a prominent patent attorney, explores the… The post Filing Strategies for Maximizing Pharma Patents appeared first on DrugPatentWatch - Make Better Decisions.

Pharma Companies

The Pharma Data

DECEMBER 20, 2020

SN14 works by targeting the coronavirus’ nucleocapsid and spike proteins to prevent viral replication using the company’s ImmunoBody DNA vaccine technology. UK drug developer Scancell said it has chosen a COVID-19 vaccine candidate, SN14, from more than a dozen potential products to advance to a clinical trial. .

Clinical Trials

Fierce BioTech

OCTOBER 25, 2023

The AI innovation race is on: Here are three strategies to ensure you’re not left behind | Biotech and pharma companies are using generative AI to improve business operations, marketing performance and research.

Pharma Companies

Drug Channels

OCTOBER 15, 2021

She highlights three key trends that pharma companies, plan sponsors, and others will consider as we head to the upcoming Asembia Specialty Pharmacy Summit (October 26 to 29 in Las Vegas). Today’s guest post comes from Jayne Hornung, Chief Clinical Officer at MMIT.

Specialty Pharmacies

Fierce BioTech

SEPTEMBER 19, 2024

Listing Image QuartzListingLogo_250x190_norstella.png Listing Introduction Real-world data is essential to gaining insights into a patient’s diagnostic journey, but many pharma companies may not be using lab data, in particular, to its full potential. On Demand Start Date Tue, 10/29/2024 - 12:00

Treatment

DrugBaron

OCTOBER 17, 2022

In practice, this looks much more like a traditional pharma company than a biotech. Global pharma companies, at least until recently, didn’t have “stories” linking assets but an uncorrelated pipeline of product candidates chosen for their individual value.

Pharma Companies

Fierce BioTech

OCTOBER 3, 2023

Discover how a top 10 pharma company is making strides in addressing this disparity by harnessing the power of H1's diversity insights to build an equitable clinical trial for cardiovascular disease.

Clinical Trials

DrugBank

JUNE 27, 2024

They also provide a level playing field for academics, biotech companies, and pharma giants to compete on. However, Pharma companies do have a some advantages when it comes to the proprietary data they have on failed or patented drugs, giving them a step ahead in exploring repurposing.

Drugs

H1 Blog

MAY 11, 2023

Omnichannel engagement for physician marketing is a powerful tool for biotechnology and pharma companies looking to increase reach and drive engagement among HCPs. By taking a tailored approach, pharma companies can ensure they’re offering meaningful information that resonates with each individual HCP.

Pharma Companies

Fierce BioTech

SEPTEMBER 30, 2024

Fierce Biotech Week Fierce Biotech Week features insights from C-suite and executive leadership at biotech, mid-sized and large pharma companies on emerging trends and market dynamics that will help effectively prioritize R&D spend, optimize drug development and clinical operations, and navigate capital raising and partnering deals.

Pharma Companies

Fierce BioTech

JULY 25, 2023

But despite the supportive landscape for rare disease therapies, pharma companies still struggle to launch on time, if at all. But despite the supportive landscape for rare disease therapies, pharma companies still struggle to launch on time, if at all.

Pharma Companies